Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03249571 · ClinicalTrials.gov registry record · NA
Flavonoids, Exercise, Gut-Derived Phenolics
A NA study, sponsored by Appalachian State University.
- Completed
- Registry status
- NA
- Development phase
- 100
- Enrollment target
NCT03249571: Completed NA study, sponsored by Appalachian State University.
NCT03249571 is a NA study that has completed, run by Appalachian State University. The registered enrollment target is 100 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03249571, a NA study, has completed, sponsored by Appalachian State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
Study Summary
PURPOSE: 1. PRIMARY: Using a randomized, parallel group design, this investigation will determine if the combination of 2-weeks polyphenol supplementation (using the Reoxcyn flavonoid supplement in capsule form) and one acute 45-minute brisk walking bout enhances the translocation of gut-derived phenolics into the circulation. A comparator group of runners (N=20) ingesting the flavonoid supplement for two weeks will be included (2.5 h run, 70% VO2max). 2. SECONDARY: Data from this study will determine if 2-weeks supplementation of the Reoxcyn flavonoid supplement is a sufficient time period to increase circulating levels of gut-derived phenolics, extending data collected from the previous 12-week community trial. HYPOTHESIS: We hypothesize that an acute 45-minute brisk walking exercise bout (60% VO2max) following 2 weeks of increased polyphenol intake will be a sufficient exercise stimulus to increase gut permeability and the movement of gut-derived phenolics into circulation. If this hypothesis is confirmed, these data would have broad public health appeal, demonstrating that the combination of brisk walking and increased polyphenol intake augments circulating levels of health-restoring small phenolic molecules derived from bacterial breakdown in the colon.
Primary Outcome
Biotransformed flavonoids by gut bacteria after ingestion
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Flavonoid supplement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2017-06-05 |
| Est. Completion | 2017-08-30 |
| Phase | NA |
What the finished NCT03249571 record still lists
NCT03249571 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03249571 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03249571 about?
NCT03249571 is a clinical study titled "Flavonoids, Exercise, Gut-Derived Phenolics". PURPOSE: 1. PRIMARY: Using a randomized, parallel group design, this investigation will determine if the combination of 2-weeks polyphenol supplementation (using the Reoxcyn flavonoid supplement in capsule form) and one acute 45-minute brisk walking bout enhances the translocation of gut-derived ph...
What is the current status of trial NCT03249571?
This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2017-06-05. Estimated completion is 2017-08-30.
What interventions are being tested in trial NCT03249571?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Flavonoid supplement (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03249571?
This trial is sponsored by Appalachian State University, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03249571's enrollment target sits among peer trials
100 840th of 2000 higher than 1,081 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI